AMOEBA (EPA:AMEBA) - AMOEBA and CONIDIA validate the effect of Willaertia Magna as a biocontrol agent for the prevention of plant diseases.

Transparency directive : regulatory news

22/11/2017 18:00

PRESS RELEASE

AMOEBA and CONIDIA validate the effect of Willaertia Magna as a biocontrol
agent for the prevention of plant diseases

Lyon, November 22nd, 2017- AMOEBA (FR0011051598 - AMEBA), producer of a
biological biocide capable of eliminating bacterial risk in water and wound
care applications, announced today the positive results of in vitro trials
conducted with Willaertia Magna C2c Maky microorganism for the control of plant
diseases.

Those in vitro trials were carried out by the company CONIDIA, recognized for
its broad expertise in fungi and their resistance to fungicides.

The results highlight the possibility to use Willaertia Magna C2c Maky as a
biocontrol agent* on pathogens resistant to fungicides, like mildew or
Botrytis, fungi that are responsible for grapevine disease. Willaertia magna
C2c Maky could therefore be used as a preventing treatment for plant
protection.

This breakthrough opens the door to an alternative to pesticides as promoted by
the 2009/128/CE European directive translated in France by the Ecophyto II
plan, that calls for reducing by half the use of pesticides by 2025. This plan
is aimed not only at reducing the risks and effects of the pesticides use on
human health and to the environment, but also to reduce dependence on
pesticides.

AMOEBA has filed a patent application and continues to develop this
application, in particular with greenhouse tests in summer 2018 followed by
tests in fields in 2019. At the end of the greenhouse tests, the Company could
start discussions on a potential partnership with a market player.

The global market for pesticides is estimated at EUR 51.2b**. The segment of
biocontrol is experiencing a growth per annum of 15 to 20% representing a
market worldwide of EUR 1.6b***.

" This work is in line with the integrated management where predicting tools to
detect plant pathogens are combined with biocontrol solutions like AMOEBA's
product. This solution perfectly matches the objectives of creating efficient
and environment friendly biocontrol tools. " stated Sébastien VACHER, Global
Manager at CONIDIA.

" We have just reached an exceptional milestone in opening a vast and new
application in agriculture. The increase in biocontrol products demand is
supported by a population becoming increasingly aware of environmental issues
and also by the performance of biocontrol solutions as an alternative to
pesticides. " added Fabrice PLASSON, Managing Director of AMOEBA.

* The biocontrol covers all the methods for crop protection using live
organisms or natural substances. It is based on the management of the
ecological balance of aggressor populations rather than their elimination using
phytochemical products.
** Worldwide Turnover of pesticides sales in 2015. Source UIPP, Repères
2016-2017.
***Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

About CONIDIA:

CONIDIA is a laboratory specialized in the study of interactions of
microorganisms with their environment. We use tools combining image analysis,
classical microbiology and molecular biology allowing us to work on a large
number of matrices (Air, water, soil ...). Thanks to our subsidiary CONIPHY
studying resistance of plant diseases agents, particularly vine and cereals
pathogens, we are today the French leader in the study of fungi in the
environment. Based at Quincieux (Lyon, France), we are working on the
development of new methods and are behind several patents for our customers.

About d'AMOEBA :

AMOEBA group's objective is to become the global leader in eliminating
waterborne bacterial risk in water treatment and wound care applications. Our
solutions represent alternatives to chemical products widely used in the
cooling water treatment and the wound care market. In a global market for
chemical biocides estimated to be worth EUR 21 bn(1) AMOEBA is focusing on the
industrial cooling tower application estimated at EUR 1.7 bn(2). Similarly, in
a global wound care market estimated at EUR 15.2bn(3), AMOEBA is targeting the
chronic wound care market in the USA, estimated to be worth EUR 751 million(4).
The use of Willaertia magna C2c Maky in health care products will be subject to
FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological
biocide for water treatment, BIOMEBA, has not yet been granted marketing
authorization in the USA, Europe and Canada. AMOEBA is taking the required
regulatory steps to be granted marketing authorization in those regions for the
use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France),
AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and
joined the CAC(r) Small index on 21st September 2015. More information on
www.amoeba-biocide.com.

(1): Sources combined by Amoeba from water treatment agencies, Freedonia,
Eurostat and MarketsandMarkets (2): Amoeba data combined from the following
sources: DRIRE 2013, Eurostat, ARHIA 2013
(3) marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User
- Global Forecast to 2021," 2016.
(4) BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017.

Contacts:

Amoéba
Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
ggasparetto@actifin.fr

source : webdisclosure.com

AMOEBA's latest news

07/10/2024 17:45

AMOEBA (EPA:AMEBA) - AMOEBA and CONIDIA validate the effect of Willaertia Magna as a biocontrol agent for the prevention of plant diseases.

Transparency directive : regulatory news

AMOEBA's latest news

Other stories